Today, Emergent BioSolutions announced the shelf-life extension for
NARCAN® Nasal Spray from three years (36 months) to four years (48
months) to all newly manufactured product. The update makes NARCAN®
Nasal Spray the only 4 mg, intranasal naloxone spray in Canada with
this extended expiration date. The Health Canada notification to
extend NARCAN® Nasal Spray’s shelf-life was completed on February
2, 2024.
Naloxone, the active ingredient in NARCAN® Nasal Spray, is a
life-saving medication that can reverse an overdose from
prescription and illicit opioids, such as heroin and fentanyl, when
given in time. As an emergency public health measure, Health Canada
first approved NARCAN® Nasal Spray in October 2016.i,ii In 2023,
Emergent distributed approximately 22 million doses (~11 million
two-dose cartons) in Canada and the U.S. through
public interest organizations, such as community-based
organizations, harm reduction groups and pharmacies. According to
the Government of Canada, there were 6,312 opioid-related
hospitalizations in 2023.iii That is a 16 percent increase compared
to the same period in 2022 and it equates to an average of 17
hospitalizations a day.iii
“Helping to save lives from accidental opioid poisonings is our
number one priority and that is why increasing awareness around the
potential risks, reducing stigma and improving access to
NARCAN® Nasal Spray are important efforts as part of the
broader solution in Canada,” said Paul Williams, SVP and products
business head, at Emergent. “We believe that Emergent’s proactive
commitment to extend the shelf-life for NARCAN® Nasal Spray
offers patients, caregivers and critical community partners the
ability to be best prepared to respond to an opioid overdose
emergency.”
In addition to increasing access to NARCAN® Nasal Spray,
Emergent also funds public awareness initiatives, supports
community organizations’ local efforts, and works closely with
governments, associations, and Indigenous communities to get
intranasal naloxone into the hands of those who need it.
NARCAN® Nasal Spray can be accessed at no cost to all residents
of Northwest Territories, Ontario, Quebec and the Yukon, through
the provincial and territorial take-home naloxone (or equivalent)
programs. It is also available through Veteran Affairs Canada,
First Nations Health Authority (FNHA) in British Columbia and
Non-Insured Health Benefits (NIHB) program. NARCAN® Nasal Spray can
also be ordered online at OrderNARCAN.ca in provinces and
territories that do not include NARCAN® Nasal Spray on their
take-home naloxone programs (or equivalent).
NARCAN® Nasal Spray is used to treat someone who has overdosed
on opioids. It can be used by anyone to reverse the effects of the
overdose until medical help arrives. Administering NARCAN® Nasal
Spray to someone who is not experiencing an overdose or does not
have opioids in their system will do no harm to the person. Always
read the label and follow the directions for use. To learn more
about this life-saving medicine and access resources, education and
advocacy tools, visit narcannasalspray.ca.
About
NARCAN® Nasal
SprayNARCAN® Nasal Spray is a pure opioid antagonist
indicated for emergency use to reverse known or suspected opioid
overdose, as manifested by respiratory and/or severe central
nervous system depression.
While NARCAN® Nasal Spray can be administered by a
non-health care professional, it is not intended to be a substitute
for professional medical care. Always call 911 as soon as an opioid
overdose is suspected, before administering NARCAN® Nasal
Spray.Always read the label and follow the directions for use.
About Emergent BioSolutionsAt Emergent,
our mission is to protect and enhance life. For 25 years, we’ve
been at work defending people from things we hope will never
happen—so we are prepared just in case they ever do. We provide
solutions for complex and urgent public health threats through a
portfolio of vaccines and therapeutics that we develop and
manufacture for governments and consumers. We also offer a range of
integrated contract development and manufacturing services for
pharmaceutical and biotechnology customers. To learn more about how
we plan to protect or enhance 1 billion lives by 2030, visit
our website and follow us
on LinkedIn, X, Instagram, Apple
Podcasts and Spotify.
Safe Harbor StatementThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical fact, are forward-looking
statements. We generally identify forward-looking statements by
using words like “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “forecast,” “future,” “goal,” “intend,”
“may,” “plan,” “position,” “possible,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would,” and similar
expressions or variations thereof, or the negative thereof, but
these terms are not the exclusive means of identifying such
statements. Forward-looking statements are based on our current
intentions, beliefs and expectations regarding future events based
on information that is currently available. We cannot guarantee
that any forward-looking statements will be accurate. Readers
should realize that if underlying assumptions prove inaccurate or
if known or unknown risks or uncertainties materialize, actual
results could differ materially from our expectations. Readers are,
therefore, cautioned not to place undue reliance on any
forward-looking statements. Any forward-looking statement speaks
only as of the date of this press release, and, except as required
by law, we do not undertake any obligation to update any
forward-looking statement to reflect new information, events or
circumstances.
There are a number of important factors that could cause the
company’s actual results to differ materially from those indicated
by any forward-looking statements. Readers should consider this
cautionary statement, as well as the risk factors and other
disclosures included in our periodic reports filed with
the U.S. Securities and Exchange Commission, when evaluating
our forward-looking statements.
Investor Contact:Richard S. LindahlExecutive
Vice President, CFOlindahlr@ebsi.com
Media Contact:Assal HellmerVice President,
Communicationsmediarelations@ebsi.com
________________________i Government of Canada. Regulatory
Decision Summary for NALOXONE HYDROCHLORIDE NASAL SPRAY.
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS00185.
Accessed July 17, 2024ii Government of Canada. Frequently Asked
Questions: Access to naloxone in Canada (including NARCAN™ Nasal
Spray)
https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/narcan-nasal-spray-frequently-asked-questions.html.
Accessed June 17, 2024. iii Government of Canada. Health Infobase:
Opioid- and Stimulant-related Harms in Canada. Updated June 28,
2024. Available at:
https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/.
Accessed May 31, 2024.
Emergent Biosolutions (NYSE:EBS)
過去 株価チャート
から 6 2024 まで 7 2024
Emergent Biosolutions (NYSE:EBS)
過去 株価チャート
から 7 2023 まで 7 2024